Evidence map›Paper›PMID 40348895›Full record

SynthesisInternational urology and nephrology2025

Comparative efficacy of expanded hemodialysis and online hemodiafiltration: a systematic review and meta-analysis.

Ozgur Aktas, Ruslan Akhmedullin, Anara Abbay, Arif E Narin, Muharrem S Yanilmaz, Candan Genc, Abduzhappar Gaipov, Adrian Covic, Mehmet Kanbay

Abstract readSystematic ReviewMeta-AnalysisComparative Study
PubMed Publisher
In one paragraph

Synthesis in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ozgur AktasDepartment of Medicine, Faculty of Medicine, Koç University, Istanbul, Turkey.
Ruslan AkhmedullinDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Anara AbbayDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Arif E NarinDepartment of Medicine, Faculty of Medicine, Koç University, Istanbul, Turkey.
Muharrem S YanilmazDepartment of Medicine, Faculty of Medicine, Koç University, Istanbul, Turkey.
Candan GencDepartment of Medicine, Faculty of Medicine, Koç University, Istanbul, Turkey.
Abduzhappar GaipovDepartment of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan.
Adrian CovicNephrology Clinic, Dialysis, and Renal Transplant Center-"C.I. Parhon" University Hospital, Iasi, Romania.
Mehmet KanbayDepartment of Internal Medicine, Division of Nephrology, Koc University School of Medicine, 34010, Istanbul, Turkey. mkanbay@ku.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimThe comparison between online hemodiafiltration (online HDF) and expanded hemodialysis (HDx) remains undetermined. This systematic review and meta-analysis were conducted to provide comparative evidence on the molecule clearance, efficacy, and all-cause mortality of HDx versus online HDF in patients with end-stage kidney disease (ESKD). MATERIALS AND

methodsA comprehensive search was conducted up to September 10, 2024, using various electronic databases PubMed, Cochrane Library, Scopus, Web of Science, and Ovid MEDLINE with adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Risk ratios (RR) for binary outcomes and standardized mean differences (Hedge's g) were used for continuous outcomes.

resultsThe meta-analysis included eight studies, consisting of 614 patients in total. No statistical difference in all-cause mortality was found between HDx and online HDF (RR 0.97; 95% Cl 0.62-1.53, p = 0.91, I

conclusionOverall, both modalities are found to be effective, but online HDF revealed superior efficacy with potential advantages in middle-molecule clearance. Further standardized, randomized, and high-quality trials are required not only to confirm these findings but also to address the substantial heterogeneity found in the clearance of prolactin, myoglobulin, and albumin loss. REGISTRATION: PROSPERO registration number: CRD42024622632.

Indexed as

HemodiafiltrationKidney Failure, ChronicRenal DialysisHumansTreatment OutcomeExpanded hemodialysisHemodialysisMedium cut-off membraneOnline hemodiafiltration

Identifiers

PMID40348895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.